AVROBIO, Inc. (AVRO): Price and Financial Metrics


AVROBIO, Inc. (AVRO): $0.84

0.05 (+6.14%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AVRO to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

AVRO Stock Price Chart Interactive Chart >

Price chart for AVRO

AVRO Price/Volume Stats

Current price $0.84 52-week high $11.00
Prev. close $0.79 52-week low $0.74
Day low $0.75 Volume 447,200
Day high $1.00 Avg. volume 691,824
50-day MA $1.13 Dividend yield N/A
200-day MA $3.41 Market Cap 36.69M

AVROBIO, Inc. (AVRO) Company Bio


AVROBIO, Inc., a clinical stage gene therapy company, focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. It lead product candidate in AVR-RD-01, which is in Phase 1 clinical trial for the treatment of Fabry disease. The company is also developing AVR-RD-02 for the treatment of Gaucher disease; AVR-RD-03 for the treatment of Pompe disease; and AVR-RD-04 for the treatment of cystinosis. The company was founded in 2015 and is based in Cambridge, Massachusetts.


AVRO Latest News Stream


Event/Time News Detail
Loading, please wait...

AVRO Latest Social Stream


Loading social stream, please wait...

View Full AVRO Social Stream

Latest AVRO News From Around the Web

Below are the latest news stories about AVROBIO Inc that investors may wish to consider to help them evaluate AVRO as an investment opportunity.

2 Net Current Asset Value Stocks to Consider

Short-term investors could be interested in these businesses

Yahoo | February 21, 2022

AVROBIO (AVRO) Presents At AVROBIO WORLD Symposium 2022 Cystinosis

No summary available.

Seeking Alpha | February 14, 2022

Needham Thinks Avrobio’s Stock is Going to Recover

In a report released today, Gil Blum from Needham maintained a Buy rating on Avrobio (AVRO – Research Report), with a price target of $8.00. The company's shares closed last Wednesday at $1.65, close to its 52-week low of $1.62. According to TipRanks.com, Blum is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -35.1% and a 13.0% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Rocket Pharmaceuticals, and Aeglea Biotherapeutics. Avrobio has an analyst consensus of Moderate Buy, with a price target consensus of $5.83, representing a 216.8% upside.

Howard Kim on TipRanks | February 10, 2022

Mizuho Securities Sticks to Their Buy Rating for Avrobio (AVRO)

In a report released today, Uy Ear from Mizuho Securities maintained a Buy rating on Avrobio (AVRO – Research Report), with a price target of $6.00. The company's shares closed last Wednesday at $1.65. According to TipRanks.com, Ear is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -14.9% and a 27.3% success rate. Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Sarepta Therapeutics, and uniQure. Avrobio has an analyst consensus of Moderate Buy, with a price target consensus of $5.83.

Catie Powers on TipRanks | February 9, 2022

After Fabry Trial Setback, Avrobio Hopes Rebound With Lysosomal Storage Disorder Data

Avrobio Inc''s (NASDAQ: AVRO ) gene therapy for a rare lysosomal storage disorder showed potential durability in the first three patients more than one year after infusion. The data comes from a Phase 1/2 trial testing the safety and efficacy of AVR-RD-04 for cystinosis who had previously been given cysteamine, which is a standard treatment that reduces the buildup of cystine crystals in … Full story available on Benzinga.com

Benzinga | February 9, 2022

Read More 'AVRO' Stories Here

AVRO Price Returns

1-mo -19.23%
3-mo -39.13%
6-mo N/A
1-year -90.40%
3-year -94.61%
5-year N/A
YTD -78.18%
2021 -72.38%
2020 -30.75%
2019 20.90%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4311 seconds.